Table 3.
Additional investigations.
| Variable, Units | n (%) | Contributory |
|---|---|---|
| Laboratory | ||
| Blood culture | 52 (91) | 0 |
| Serology | 48 (84) | 1 |
| Hepatitis B and C viruses | 39 (68) | 0 |
| Coxiella burnetii | 20 (35) | 1 |
| Anti-neutrophil cytoplasmic antibodies | 41 (72) | 3 |
| Rheumatoid factors | 30 (53) | 0 |
| Tuberculin skin test or QuantiFERON® | 24 (42) | 0 |
| Tumor markers | 9 (16) | 0 |
| Ultrasonography | ||
| Transthoracic echocardiography | 30 (53) | 0 |
| Additional transesophageal echocardiography | 8 (14) | 1 |
| Doppler ultrasound venous of the lower limbs | 9 (16) | 0 |
| Computerized tomography | ||
| Thoracic–abdominal computed tomography (CT) | 9 (16) | 2 |
| Additional thoracic CT angiography | 6 (11) | 1 |
| 18-FDG-PET/CT | 42 (74) | 12 |
| Endoscopy | ||
| Gastroscopy | 35 (61) | 0 |
| Colonoscopy | 30 (53) | 0 |
| Bronchial fibroscopy | 16 (28) | 0 |
| Pathology | ||
| Bone marrow aspiration | 19 (33) | 3 |
| Bone marrow biopsy | 16 (28) | 1 |
| Temporal artery biopsy | 23 (40) | 5 |
| Lymph node biopsy | 13 (23) | 6 |
| Skin biopsy | 5 (9) | 1 |
| Muscle biopsy | 1 (2) | 1 |
| Molecular biology | 16 (28) | 0 |